Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
A Randomized Study of Sulindac in Oral Premalignant Lesions
This study is currently recruiting participants.
Study NCT00299195 Information provided by Memorial Sloan-Kettering Cancer Center
First Received: March 2, 2006 Last Updated: November 5, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukoplakia, Oral
Benign Neoplasms
Additional conditions recognized in this trial
Brain Neoplasms
Leukoplakia
Neoplasms
More general conditions related to this trial
Brain Diseases
Central Nervous System Diseases
Central Nervous System Neoplasms
Head and Neck Neoplasms
Mouth Diseases
Mouth Neoplasms
Neoplasms by Site
Nervous System Diseases
Nervous System Neoplasms
Pathological Conditions, Anatomical
Precancerous Conditions
Stomatognathic Diseases
Interventions listed in this trial
sulindac
Placebo
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antineoplastic Agents
Antirheumatic Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Memorial Sloan-Kettering Cancer Center
Head and Neck Surgery, AIMS, Cochin, India
Weill Medical College of Cornell University
Regional Cancer Centre (RCC), Trivandrum, India
Back to top of Main Content
